GlobalData on MSN1d
FDA accepts priority review of Apellis’ Empaveli sNDA for kidney diseasesApellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of ...
The supplemental New Drug Application for the C3G and IC-MPGN indications is supported by data from the phase 3 VALIANT study.
Sanofi (NASDAQ:SNY) said on Tuesday that the US FDA has granted priority review to the regulatory submission of tolebrutinib ...
April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation of the ...
A decision on tolebrutinib for treating MS is now set for Sept. 28, after the FDA granted priority review to its approval ...
(RTTNews) - Apellis Pharmaceuticals, Inc. (APLS) Tuesday said that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for the supplemental New Drug Application ...
The FDA has accepted for Priority Review the BLA for apitegromab for the improvement of motor function in patients with spinal muscular atrophy.
Southwest Rapid Rewards Priority Credit Card Introduction The Southwest Rapid Rewards® Priority Credit Card packs plenty of perks. If you’re considering applying for it, here’s the most ...
The U.S. Food and Drug Administration (FDA) has accepted Apellis Pharmaceuticals, Inc.’s (NASDAQ: APLS) supplemental New Drug Application (sNDA) and granted Priority Review designation to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback